[go: up one dir, main page]

CY1119549T1 - Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου - Google Patents

Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου

Info

Publication number
CY1119549T1
CY1119549T1 CY20171100876T CY171100876T CY1119549T1 CY 1119549 T1 CY1119549 T1 CY 1119549T1 CY 20171100876 T CY20171100876 T CY 20171100876T CY 171100876 T CY171100876 T CY 171100876T CY 1119549 T1 CY1119549 T1 CY 1119549T1
Authority
CY
Cyprus
Prior art keywords
cancer
cancer treatment
therapy including
including clinical
cognitive therapy
Prior art date
Application number
CY20171100876T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Rita Mitnacht-Kraus
Stefan Denis JACOBS
Magdalena Jadwiga UTSCH
Cornelia Adriana Maria HEINZ
Christiane Regina STADLER
Original Assignee
Ganymed Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119549(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/002210 external-priority patent/WO2013174403A1/en
Application filed by Ganymed Pharmaceuticals Gmbh filed Critical Ganymed Pharmaceuticals Gmbh
Publication of CY1119549T1 publication Critical patent/CY1119549T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει συνδυαστική θεραπεία για την αποτελεσματική αγωγή και/ή πρόληψη ασθενειών που συνδέονται με κύτταρα που εκφράζουν την CLDN18.2, συμπεριλαμβανομένων καρκινικών παθήσεων όπως ο καρκίνος του στομάχου, ο καρκίνος του οισοφάγου, ο καρκίνος του παγκρέατος, ο καρκίνος των πνευμόνων, ο καρκίνος των ωοθηκών, ο καρκίνος του κόλου, ο καρκίνος του ήπατος, ο καρκίνος κεφαλής-λαιμού, και ο καρκίνος της χοληδόχου κύστεως, και μεταστάσεων αυτών.
CY20171100876T 2012-05-23 2017-08-17 Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου CY1119549T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/002210 WO2013174403A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP13724523.9A EP2852408B1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
PCT/EP2013/001504 WO2013174510A1 (en) 2012-05-23 2013-05-21 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
CY1119549T1 true CY1119549T1 (el) 2018-03-07

Family

ID=52544200

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100876T CY1119549T1 (el) 2012-05-23 2017-08-17 Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
CY20201101136T CY1123593T1 (el) 2012-05-23 2020-11-30 Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201101136T CY1123593T1 (el) 2012-05-23 2020-11-30 Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου

Country Status (9)

Country Link
EP (4) EP4364756A3 (el)
CY (2) CY1119549T1 (el)
DK (1) DK3254695T3 (el)
HR (1) HRP20171218T1 (el)
ME (1) ME02932B (el)
PL (2) PL3254695T3 (el)
RS (1) RS56187B1 (el)
SI (1) SI2852408T1 (el)
SM (1) SMT201700387T1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02932B (me) 2012-05-23 2018-04-20 Ganymed Pharmaceuticals Gmbh Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
US11555070B2 (en) * 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
US20220033491A1 (en) 2018-09-30 2022-02-03 Cafa Therapeutics Limited Combination therapy of cldn18 antibody and chemotherapy drugs
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
CN115073596A (zh) * 2021-03-10 2022-09-20 上海莱馥医疗科技有限公司 一种人源化Claudin 18.2抗体及其应用
CN114685670A (zh) * 2020-12-31 2022-07-01 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR20090088973A (ko) 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US8445219B2 (en) * 2008-07-25 2013-05-21 Merck Patent Gmbh Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
ME02932B (me) 2012-05-23 2018-04-20 Ganymed Pharmaceuticals Gmbh Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Also Published As

Publication number Publication date
PL2852408T3 (pl) 2017-12-29
EP2852408A1 (en) 2015-04-01
EP3791896A1 (en) 2021-03-17
SMT201700387T1 (it) 2017-09-07
EP4364756A3 (en) 2024-07-31
HRP20171218T1 (hr) 2017-10-20
SI2852408T1 (sl) 2017-10-30
ME02932B (me) 2018-04-20
PL3254695T3 (pl) 2021-04-06
RS56187B1 (sr) 2017-11-30
EP3791896B1 (en) 2024-01-10
EP3254695B1 (en) 2020-09-09
EP2852408B1 (en) 2017-05-17
CY1123593T1 (el) 2022-03-24
EP3254695A1 (en) 2017-12-13
EP4364756A2 (en) 2024-05-08
DK3254695T3 (da) 2020-11-30

Similar Documents

Publication Publication Date Title
CY1119549T1 (el) Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
CY1124965T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
MX2019013723A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CY1118874T1 (el) Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
MX2017013075A (es) Conjugados de farmaco que comprenden anticuerpos contra claudina 18.2.
CY1123192T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldν6)
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
MX2020011768A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CY1114458T1 (el) Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
CY1124006T1 (el) Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου
TW201613643A (en) Anti-CDH6 antibody drug conjugates
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
EA201791745A1 (ru) Производные тетрагидропиранилбензамида
CY1120255T1 (el) Αντισωμα αντι-β7-η3